Pharmicell Co., Ltd. (KRX:005690)

South Korea flag South Korea · Delayed Price · Currency is KRW
19,800
+870 (4.60%)
Apr 28, 2026, 3:30 PM KST
96.43%
Market Cap 1.19T
Revenue (ttm) 23.94B
Net Income (ttm) -26.78B
Shares Out 60.00M
EPS (ttm) -613.75
PE Ratio n/a
Forward PE n/a
Dividend 50.00 (0.27%)
Ex-Dividend Date Dec 29, 2025
Volume 2,503,302
Average Volume 1,120,032
Open 19,000
Previous Close 18,930
Day's Range 18,530 - 20,300
52-Week Range 9,950 - 20,800
Beta 0.58
RSI 64.31
Earnings Date n/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impot... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1968
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 005690
Full Company Profile

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.

Financial Statements

News

There is no news available yet.